Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy followed by camrelizumab in elderly patients with locally advanced esophageal cancer
ChiCTR2000033622Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in esophageal cancer, sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoint: overall survival. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2000033622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033622.